To examine the effect of carboplatin on testicular function, carboplatin was administered to mature male Sprague-Dawley rats. Four weeks after carboplatin treatment, the serum level of follicle-stimulating hormone (FSH) significantly increased in animals treated with 30 mg kg-1 carboplatin (p < 0.02). After 8 weeks of administration, the sperm count and motility in the cauda epididymis decreased in the rats treated with 30 mg kg-1 carboplatin (p < 0.005 and p < 0.05, respectively). The percentage of a-type tubules and the diameter of seminiferous tubules were also significantly reduced in the group treated with 30 mg kg-1 carboplatin (p < 0.02 and p < 0.01, respectively). The serum levels of luteinizing hormone and testosterone were not changed, although the serum level of FSH increased in the animals treated with 20 and 30 mg kg-1 carboplatin (each, p < 0.005). All parameters returned to normal values 12 weeks after the treatment. In conclusion, carboplatin impairs spermatogenesis by possibly damaging the spermatogonia and Sertoli cells but does not affect the Leydig cell function.

Keywords:
Carboplatin, Rat, Spermatogenesis
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.